Effective price per mg uses an active dated override first, then the row-level historical discount, then the vendor default from the same Git revision. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.

Price watch · beta

Let the market come to you.

Watch the best market price or one vendor. Get one email when Sermorelin crosses your target, drops, or sets a new tracked low—without daily noise.

Price scopeAlert meTarget per mg

$/mg

Confirmed Weekly Peptide Intel email

Requires a confirmed Weekly Peptide Intel address, then a separate alert confirmation. Already watching? Manage price alerts. Public prices can change; confirm the final cart total.

Public product evidence233 certificate records mentioning this compound or product name113 provider-linked · 188 exact product matches

Status

Research Market

This name primarily lives in the research market and should not be read like an approved pharmaceutical product.

Research area

GH axis / secretagogue research

Primary research area: GH axis. Also surfaces under Performance for browsing and discovery.

Aliases

Sermorelin Acetate, Geref

Signal depth

Medium

No FDA label signal · 42 trials · 34 PubMed results

Preclinical

Research evidence

Current evidence for Sermorelin is limited to laboratory or animal studies — there are no name-matched human trials with reported results. Any claims about effects in people are not yet backed by clinical data.

Sermorelin has no clinical trials that name it and 34 PubMed-indexed publications and is not FDA-approved. Current evidence is preclinical or mechanistic.

Human data

Lab / animal only

Trial quality

No human trials

Outcomes

No human trials

Replication

Multiple papers

Literature

High-impact

The Journal of Clinical Endocrinology & Metabolism · 52 citationsOnce daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group.BioDrugs · 31 citationsSermorelin Case ReportsAnterior cervical osteophyte-related dysphagia in a long-term growth hormone user: a case report.Journal ArticleThe emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.Journal ArticleSafety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.Journal ArticleA new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review.

Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-09-08 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What sermorelin is

Sermorelin is a growth hormone-releasing hormone analogue that sits closer to the clinical side of the GH category than many generic secretagogues. It is still common in vendor listings and wellness-adjacent peptide conversations.

Why it matters

It helps bridge the gap between older hormone-therapy language and today’s research-market catalog culture.

Regulatory context

Sermorelin products widely sold through peptide vendors should be understood as unapproved retail-market offerings, not as interchangeable with any prior medical or diagnostic context.

Practical reading note

Sermorelin is a good reminder that a compound can have a more serious historical footing than the average peptide listing while still being marketed in ways that go far beyond that footing.